Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy - Report - MDSpire
Advertisement
Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy
Swift Clearance of SARS-CoV-2 via Intramuscular or Intravenous Monoclonal Antibodies
Overview
This study demonstrates that both intramuscular (IM) and intravenous (IV) administration of tixagevimab/cilgavimab (T/C) rapidly clear culturable SARS-CoV-2 in early COVID-19 patients, with minimal emergence of resistance mutations. IM delivery showed comparable virologic efficacy to IV, supporting its use as a scalable alternative.
Background
Monoclonal antibodies (mAbs) have been effective in treating COVID-19, particularly for patients ineligible for oral antivirals. Traditionally, mAbs require intravenous infusion, limiting scalability due to infrastructure and personnel needs. Intramuscular administration offers a practical alternative with comparable systemic exposure, but its virologic efficacy against SARS-CoV-2 had not been fully evaluated. This study addresses this gap by comparing viral culture clearance and resistance emergence between IM and IV T/C delivery in early SARS-CoV-2 infection.
Data Highlights
Parameter
IM T/C
IV T/C
Placebo
Baseline AN SARS-CoV-2 RNA (log10 copies/mL)
Comparable across groups
Comparable across groups
Comparable across groups
Culture positivity Day 1 (%)
6.3%
6.3%
62%
Culture positivity Day 2 (%)
0%
0%
50%
Median time to culture conversion (days)
≤1.0
≤1.0
2.5
Emergence of resistance mutations (%)
1.0% (treatment) vs 1.8% (placebo)
0% (both groups)
1.8% (IM placebo)
Key Findings
Both IM and IV administration of T/C rapidly eliminated culturable SARS-CoV-2 within 1 day compared to 2.5 days in placebo.
Culture positivity on day 1 was significantly lower in mAb-treated groups (6.3%) versus placebo (62%).
By day 2, no mAb-treated participants remained culture positive, while 50% of placebo participants did.
Emergence of resistance-associated spike gene mutations was rare and similar between treatment and placebo groups.
IM administration achieved virologic outcomes comparable to IV, supporting its use as a simpler delivery method.
Clinical Implications
Intramuscular delivery of tixagevimab/cilgavimab offers a practical and effective alternative to intravenous infusion for early COVID-19 treatment, enabling broader and more scalable outpatient use. Rapid viral clearance with minimal resistance emergence suggests potential benefits in reducing transmission and improving pandemic response logistics.
Conclusion
Intramuscular administration of antiviral monoclonal antibodies achieves swift clearance of culturable SARS-CoV-2 with minimal resistance, matching intravenous efficacy. This supports IM delivery as a viable, scalable treatment option for early COVID-19.
References
ACTIV-2/A5401 Trial Data and Supplementary Information
by Rinki Deo, Manish C Choudhary, Owen T Glover, Rachel Bender Ignacio, Julie Boucau, Kara W Chew, Carlee Moser, Judith S Currier, Joseph J Eron, Arzhang Cyrus Javan, Mark J Giganti, Evgenia Aga, Michael Gibbs, Taylor Cohen, Katie Streicher, Karina Soboleva, Courtney V Fletcher, Eric S Daar, Alexander L Greninger, Robert W Coombs, William Fischer, Michael D Hughes, Davey Smith, David Alain Wohl, Amy K Barczak, Jonathan Z Li, for the ACTIV-2/A5401 Study Team
